About thymalfasin (ZADAXIN)

[Guest guest]

http://money.cnn.com/news/newsfeeds/articles/marketwire/0563926.htm

About thymalfasin (ZADAXIN)

ZADAXIN, scientifically referred to as thymalfasin or thymosin alpha 1, is

SciClone's synthetic preparation of thymalfasin, a peptide produced by the

thymus gland which circulates in the blood naturally, and is instrumental in the

immune response to certain cancers and viral infections. Published scientific

and clinical studies have shown that thymalfasin helps stimulate and direct the

body's immune response to eradicate infectious diseases like HCV and HBV, as

well as certain cancers.

Thymalfasin works by stimulating a number of immune system responses and also

elicits direct antiviral and anti-cancer effects. Within the immune system,

thymalfasin stimulates stem cell differentiation and increases production of

disease-fighting T cells, including CD4, CD8, and natural killer cells.

Simultaneously it slows the breakdown and removal of these T cells. It also

increases production of T-helper cells which allow the immune system to tag and

identify invasive agents. Thymalfasin increases the production of proteins that

stimulate T cell creation while decreasing production of certain proteins which

are counterproductive in the fight against chronic viral infections.

Additionally, thymalfasin helps dramatically slow down viral replication,

allowing the strengthened immune system to more efficiently destroy virally

infected cells.

In late 2008, SciClone and the FDA reached agreement in form of a Special

Protocol Assessment on the design of a phase 3 registration trial for

thymalfasin as a potential treatment for stage IV melanoma. Thymalfasin's

potential beneficial role in treatment of melanoma derives from its demonstrated

activation of the immune system through effects on Toll-like receptor 9 and

signaling through increases in the nuclear factor NfKB, leading to increases in

tumor-infiltrating lymphocytes, specific anti-tumor cytotoxic lymphocytes, and

expression of MHC Class cell-surface molecules. Evaluation of thymalfasin's

utility in melanoma animal models has confirmed effective anti-tumor activity.

ZADAXIN is currently approved in more than 30 countries worldwide to treat a

variety of indications. In clinical and non-clinical studies, more than 4,000

patients with viral hepatitis B and hepatitis C, primary immunodeficiency

diseases, and numerous cancers have been treated with ZADAXIN with virtually no

drug-related side effects.

[Guest guest]

http://money.cnn.com/news/newsfeeds/articles/marketwire/0563926.htm

About thymalfasin (ZADAXIN)

ZADAXIN, scientifically referred to as thymalfasin or thymosin alpha 1, is

SciClone's synthetic preparation of thymalfasin, a peptide produced by the

thymus gland which circulates in the blood naturally, and is instrumental in the

immune response to certain cancers and viral infections. Published scientific

and clinical studies have shown that thymalfasin helps stimulate and direct the

body's immune response to eradicate infectious diseases like HCV and HBV, as

well as certain cancers.

Thymalfasin works by stimulating a number of immune system responses and also

elicits direct antiviral and anti-cancer effects. Within the immune system,

thymalfasin stimulates stem cell differentiation and increases production of

disease-fighting T cells, including CD4, CD8, and natural killer cells.

Simultaneously it slows the breakdown and removal of these T cells. It also

increases production of T-helper cells which allow the immune system to tag and

identify invasive agents. Thymalfasin increases the production of proteins that

stimulate T cell creation while decreasing production of certain proteins which

are counterproductive in the fight against chronic viral infections.

Additionally, thymalfasin helps dramatically slow down viral replication,

allowing the strengthened immune system to more efficiently destroy virally

infected cells.

In late 2008, SciClone and the FDA reached agreement in form of a Special

Protocol Assessment on the design of a phase 3 registration trial for

thymalfasin as a potential treatment for stage IV melanoma. Thymalfasin's

potential beneficial role in treatment of melanoma derives from its demonstrated

activation of the immune system through effects on Toll-like receptor 9 and

signaling through increases in the nuclear factor NfKB, leading to increases in

tumor-infiltrating lymphocytes, specific anti-tumor cytotoxic lymphocytes, and

expression of MHC Class cell-surface molecules. Evaluation of thymalfasin's

utility in melanoma animal models has confirmed effective anti-tumor activity.

ZADAXIN is currently approved in more than 30 countries worldwide to treat a

variety of indications. In clinical and non-clinical studies, more than 4,000

patients with viral hepatitis B and hepatitis C, primary immunodeficiency

diseases, and numerous cancers have been treated with ZADAXIN with virtually no

drug-related side effects.

[Guest guest]

http://money.cnn.com/news/newsfeeds/articles/marketwire/0563926.htm

About thymalfasin (ZADAXIN)

ZADAXIN, scientifically referred to as thymalfasin or thymosin alpha 1, is

SciClone's synthetic preparation of thymalfasin, a peptide produced by the

thymus gland which circulates in the blood naturally, and is instrumental in the

immune response to certain cancers and viral infections. Published scientific

and clinical studies have shown that thymalfasin helps stimulate and direct the

body's immune response to eradicate infectious diseases like HCV and HBV, as

well as certain cancers.

Thymalfasin works by stimulating a number of immune system responses and also

elicits direct antiviral and anti-cancer effects. Within the immune system,

thymalfasin stimulates stem cell differentiation and increases production of

disease-fighting T cells, including CD4, CD8, and natural killer cells.

Simultaneously it slows the breakdown and removal of these T cells. It also

increases production of T-helper cells which allow the immune system to tag and

identify invasive agents. Thymalfasin increases the production of proteins that

stimulate T cell creation while decreasing production of certain proteins which

are counterproductive in the fight against chronic viral infections.

Additionally, thymalfasin helps dramatically slow down viral replication,

allowing the strengthened immune system to more efficiently destroy virally

infected cells.

In late 2008, SciClone and the FDA reached agreement in form of a Special

Protocol Assessment on the design of a phase 3 registration trial for

thymalfasin as a potential treatment for stage IV melanoma. Thymalfasin's

potential beneficial role in treatment of melanoma derives from its demonstrated

activation of the immune system through effects on Toll-like receptor 9 and

signaling through increases in the nuclear factor NfKB, leading to increases in

tumor-infiltrating lymphocytes, specific anti-tumor cytotoxic lymphocytes, and

expression of MHC Class cell-surface molecules. Evaluation of thymalfasin's

utility in melanoma animal models has confirmed effective anti-tumor activity.

ZADAXIN is currently approved in more than 30 countries worldwide to treat a

variety of indications. In clinical and non-clinical studies, more than 4,000

patients with viral hepatitis B and hepatitis C, primary immunodeficiency

diseases, and numerous cancers have been treated with ZADAXIN with virtually no

drug-related side effects.

[Guest guest]

http://money.cnn.com/news/newsfeeds/articles/marketwire/0563926.htm

About thymalfasin (ZADAXIN)

ZADAXIN, scientifically referred to as thymalfasin or thymosin alpha 1, is

SciClone's synthetic preparation of thymalfasin, a peptide produced by the

thymus gland which circulates in the blood naturally, and is instrumental in the

immune response to certain cancers and viral infections. Published scientific

and clinical studies have shown that thymalfasin helps stimulate and direct the

body's immune response to eradicate infectious diseases like HCV and HBV, as

well as certain cancers.

Thymalfasin works by stimulating a number of immune system responses and also

elicits direct antiviral and anti-cancer effects. Within the immune system,

thymalfasin stimulates stem cell differentiation and increases production of

disease-fighting T cells, including CD4, CD8, and natural killer cells.

Simultaneously it slows the breakdown and removal of these T cells. It also

increases production of T-helper cells which allow the immune system to tag and

identify invasive agents. Thymalfasin increases the production of proteins that

stimulate T cell creation while decreasing production of certain proteins which

are counterproductive in the fight against chronic viral infections.

Additionally, thymalfasin helps dramatically slow down viral replication,

allowing the strengthened immune system to more efficiently destroy virally

infected cells.

In late 2008, SciClone and the FDA reached agreement in form of a Special

Protocol Assessment on the design of a phase 3 registration trial for

thymalfasin as a potential treatment for stage IV melanoma. Thymalfasin's

potential beneficial role in treatment of melanoma derives from its demonstrated

activation of the immune system through effects on Toll-like receptor 9 and

signaling through increases in the nuclear factor NfKB, leading to increases in

tumor-infiltrating lymphocytes, specific anti-tumor cytotoxic lymphocytes, and

expression of MHC Class cell-surface molecules. Evaluation of thymalfasin's

utility in melanoma animal models has confirmed effective anti-tumor activity.

ZADAXIN is currently approved in more than 30 countries worldwide to treat a

variety of indications. In clinical and non-clinical studies, more than 4,000

patients with viral hepatitis B and hepatitis C, primary immunodeficiency

diseases, and numerous cancers have been treated with ZADAXIN with virtually no

drug-related side effects.